Universe · entity
Versant Venture Management, LLC
Institutional manager (13F) · CIK 1560009
13F holdings · as of 2026-03-31 · top 8 · reported portfolio $141M
| # | Issuer | Value | Shares |
|---|---|---|---|
| 1 | Monte Rosa Therapeutics, Inc. | $52M | 3,180,780 |
| 2 | Century Therapeutics, Inc. | $27M | 12,166,109 |
| 3 | Lenz Therapeutics, Inc. | $24M | 2,656,888 |
| 4 | Jade Biosciences, Inc. | $21M | 1,525,820 |
| 5 | Contineum Therapeutics, Inc. | $7M | 542,628 |
| 6 | CRISPR Therapeutics AG | $7M | 148,831 |
| 7 | Skye Bioscience, Inc. | $1M | 2,007,704 |
| 8 | Tempest Therapeutics, Inc. | $442k | 269,772 |
Source: sec_edgar_13f · public regulatory · retrieved 2026-06-29. Public SEC data; no contact information.